Cargando…

Correction: HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy

Detalles Bibliográficos
Autores principales:	Ma, Juan, Han, Huamin, Liu, Deruo, li, Wei, Feng, Hongxiang, Xue, Xin, Wu, Xiaoran, Niu, Ge, Zhang, Ge, Zhao, Yunfeng, Liu, Changzhen, Tao, Hua, Gao, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774071/ http://dx.doi.org/10.1371/annotation/611f44b7-e349-4e7f-9dfe-bdfc724c2f4c

Ejemplares similares

HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
por: Ma, Juan, et al.
Publicado: (2013)

B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
por: Ma, Juan, et al.
Publicado: (2016)

Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2018)

Correction: Uniportal video-assisted anatomical segmentectomy: an analysis of the learning curve
por: Han, Yu, et al.
Publicado: (2023)

Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
por: Zhang, Ge, et al.
Publicado: (2014)

Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody
por: Wang, Lei, et al.
Publicado: (2013)

MiR‐34b‐3p represses cell proliferation, cell cycle progression and cell apoptosis in non‐small‐cell lung cancer (NSCLC) by targeting CDK4
por: Feng, Hongxiang, et al.
Publicado: (2019)

Correction to: Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden
por: Femel, Julia, et al.
Publicado: (2022)

Correction: Withania somnifera Root Extract Has Potent Cytotoxic Effect against Human Malignant Melanoma Cells
por: Halder, Babli, et al.
Publicado: (2015)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity
por: Cheli, Yann, et al.
Publicado: (2021)

Correction: Frequent MAGE Mutations in Human Melanoma
por: Caballero, Otavia L., et al.
Publicado: (2010)

The immunostimulatory effects of retinoblastoma cell supernatant on dendritic cells
por: Ma, Juan, et al.
Publicado: (2014)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
por: Yang, Yang, et al.
Publicado: (2023)

Correction: Cytotoxic Edema and Adverse Clinical Outcomes in Patients with Intracerebral Hemorrhage
por: Li, Na, et al.
Publicado: (2022)

Correction: Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3
por: Zhang, T., et al.
Publicado: (2019)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

Publisher Correction: Profiling and promise of supermeres
por: Clancy, James W., et al.
Publicado: (2022)

Correction: Dermoscopy of Melanomas on the Trunk and Extremities in Asians
por: Mun, Je-Ho, et al.
Publicado: (2016)

Correction to: Targeted radiotherapy of pigmented melanoma with (131)I-5-IPN
por: Xu, Xiaodong, et al.
Publicado: (2019)

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2015)

Correction to: RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2019)

Correction: Correlation between cellular uptake and cytotoxicity of polystyrene micro/nanoplastics in HeLa cells: A size-dependent matter
por: Ruan, Yiming, et al.
Publicado: (2023)

Correction: HEWL interacts with dissipated oleic acid micelles, and decreases oleic acid cytotoxicity
por: Huang, Qin, et al.
Publicado: (2019)

Correction to: COVID-19 research: promising tracks leading to uro-oncology
por: Fazekas, Tamás, et al.
Publicado: (2020)

Correction to: Targeting hypoxia in tumor: a new promising therapeutic strategy
por: Bosco, Maria Carla, et al.
Publicado: (2020)

Correction to: Microbial diversity of saline environments: searching for cytotoxic activities
por: Díaz-Cárdenas, Carolina, et al.
Publicado: (2018)

Correction: Cellular cytotoxicity is a form of immunogenic cell death
Publicado: (2020)

Author Correction: Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer
por: Hao, Xiang-lin, et al.
Publicado: (2019)

Correction to: miR-3928v is induced by HBx via NF-κB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3
por: Zhang, Qiaoge, et al.
Publicado: (2020)

Correction: Differential roles of gangliosides in malignant properties of melanomas
Publicado: (2019)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Correction: Differences in cutaneous melanoma treatment and patient satisfaction
por: Wikstrom, Jakob D., et al.
Publicado: (2021)

Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation
por: Perotti, V., et al.
Publicado: (2019)

Correction: Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
por: Ma, Jui-Wen, et al.
Publicado: (2019)

Correction: Evaluating prognosis by CK7 differentiating renal cell carcinomas from oncocytomas can be used as a promising tool for optimizing diagnosis strategies
por: Ma, Fuling, et al.
Publicado: (2018)

Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer
por: Xu, Naiqing, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_drqq09u8lpgtd4sqj81ndmiqrr